Order Article Reprints

Hammer A, Krammel M, Aigner P, Pfenneberger G, Schnaubelt S, Hofer F, Kazem N, Koller L, Steinacher E, Baumer U, et al. The Impact of Preclinical High Potent P2Y₁₂ Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine. 2023; 12(12):4094. https://doi.org/10.3390/jcm12124094

Hammer, Andreas, Mario Krammel, Patrick Aigner, Georg Pfenneberger, Sebastian Schnaubelt, Felix Hofer, Niema Kazem, Lorenz Koller, Eva Steinacher, Ulrike Baumer, and et al. 2023. "The Impact of Preclinical High Potent P2Y₁₂ Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome" Journal of Clinical Medicine 12, no. 12: 4094. https://doi.org/10.3390/jcm12124094

Hammer, A., Krammel, M., Aigner, P., Pfenneberger, G., Schnaubelt, S., Hofer, F., Kazem, N., Koller, L., Steinacher, E., Baumer, U., Hengstenberg, C., Niessner, A., & Sulzgruber, P. (2023). The Impact of Preclinical High Potent P2Y₁₂ Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 12(12), 4094. https://doi.org/10.3390/jcm12124094